2. Venkitaraman R, Joseph T, Dhadda A, et al. Prognosis of patients with triple-negative breast cancer and brain metastasis. Clin Oncol (R Coll Radiol). 2009 Nov;21(9):729-30. 3. Ivanova M, Porta FM, Giugliano F, ...
7. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429-34. 8. Brouckaert O, Wildiers H, Floris G, et al. Upda...
[3] https://seer.cancer.gov/statfacts/html/breast-subtypes.html [4] Frenel J-S, Lusque A, Mailliez A, Bachelot T, Uwer L, Mouret-Reynier MA, et al. HER2-low metastatic breast cancer (MBC): management and p...
[8] Frenel J-S, Lusque A, Mailliez A, Bachelot T, Uwer L, Mouret-Reynier MA, et al. HER2-low metastatic breast cancer (MBC): management and prognosis of a new breast cancer entity in a real-world setting. Ann On...
[4] Gampenrieder SP, Dezentjé V, Lambertini M, et al. Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group. ESMO Open. 2023 Feb;8(1):100747. ...
TNBC is notoriously hard to treat. It’s associated with poorprognosisand has no available targeted therapies because patients lack common markers. AL101, if successful, could serve as an option for some of those patients with Notch-activating genetic alterations. ...
Tumor infiltrat- ing lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). Oncoimmunology 2015; 4(9): e985930.Adams S, Goldstein LJ, Sparano JA, Demaria S, Badve SS. Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative ...
[4] Frenel J-S, Lusque A, Mailliez A, Bachelot T, Uwer L, Mouret-Reynier MA, et al. HER2-low metastatic breast cancer (MBC): management and prognosis of a new breast cancer entity in a real-world setting. Ann Oncol. 2021;32(5):S491. ...
Background:Locally advanced unresectable or metastatic TNBC is highly aggressive and has a poor prognosis. Ivonescimab, a tetravalent bispecific antibody targeting PD-1 and VEGF, has the potential to produce synergistic anti-tumor effects through both pathways via cooperative binding. This study aimed...
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with a poor prognosis. The natural compound pristimerin has shown promising anti-tumor effect. Here, it is found that pristimerin significantly triggered the activation of autophagy initiation and induced apoptosis in TNBC. ...